October 2024
Corporate presentation
Warning / Disclaimer
and Cautionary Statements
This document and the results conference call (including the question and answer session) may contain forward-looking statements and information (hereinafter "Statements") relating to ATRYS HEALTH, S.A., or the ATRYS Group (hereinafter "ATRYS", the "Company" or the "Group"). These statements may include financial projections and estimates with assumptions, statements regarding plans, objectives, and expectations that may relate to various matters, including, but not limited to, the customer base and its evolution, the growth of the various lines of business, market share, the company's results and other aspects relating to the company's activity and situation.
The forward-looking statements or forecasts contained in this document may be identified, in certain cases, by the use of words such as "expects", "anticipates", "intends", "believes" or similar language, or their corresponding negative form, or by the predictive nature of matters relating to strategies or plans or intentions. These forward-looking statements or forecasts reflect the views of ATRYS with respect to future events and are not, by their nature, guarantees of future performance and are subject to risks and uncertainties that could cause actual developments and results to differ materially from those expressed in these intentions, expectations or forecasts. Such risks and uncertainties include those identified in the documents with more complete information filed by ATRYS with the various supervisory bodies of the securities markets on which its shares are listed, and in particular, with the Spanish Securities Market Commission (CNMV).
Except to the extent required by applicable law, ATRYS undertakes no obligation to publicly update the outcome of any revisions it may make to these statements to conform to events or circumstances after the date hereof, including, without limitation, changes in the Company's business, its business development strategy or any other circumstances that may arise. This document may contain summary financial information, non-GAAP or unaudited information. The information contained herein should be read as a whole and is subject to all publicly available information about the Company, including, where applicable, other documents issued by the Company containing more complete information.
Finally, it is noted that neither this document nor anything contained herein constitutes an offer to buy, sell or exchange, or a solicitation of an offer to buy,
sale or exchange of securities, or a recommendation or advice on any security.
Atrys, 360º Health Services
We are a global healthcare provider offering innovative and personalized solutions for each patient. We performed more than 7.6
million medical procedures.
BUSINESS AREAS | 2016 | 2024 | ||||
✓ | Monitoring 1M people. | |||||
✓ | 210 care centers | |||||
P | reventive Med | icine | ||||
- OF SALES
39%
✓ Telediagnosis | ||
Diagnosis | ✓ 1 Anatomic Pathology Lab | |
✓ 1 center for radiation oncology | ||
Oncology | ||
- 7M Telediagnostics
- 5 Anatomic Pathology and Genetics Labs
- 4 Nuclear Medicine Centers
- Clinical trials
- Management of +40 oncology services
- 3 radiation oncology centers
- Clinical trials
32%
29%
GEOGRAPHIC PRESENCE: | Spain | Spain, Portugal, Chile, Colombia, |
Colombia, Peru, Brazil and Mexico |
3
Guidance 2024
Turnover | Adjusted EBITDA evolution (MAR) |
Figures in EUR million. | Figures in EUR million. |
+9-11% | |||||||||||||
202 | 220-224 | ||||||||||||
158 | |||||||||||||
107 | +10-15% | ||||||||||||
33 | 43 | 47-49 | |||||||||||
11 | 20,8 | ,13 | 21 | ||||||||||
7,3 | 3,3 | 7 | |||||||||||
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Guidance | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Guidance |
2024 | 2024 |
Financial years 2021 / 2022 and 2023 exclude Conversia (Compliance) and Atrys Switzerland. | 4 |
(MAR ) See definitions of alternative performance measures in Annex II.
A history of success
In the last 5 years ATRYS has established itself as a global consolidator aggregating 17 companies
to lead in the precision medicine and preventive medicine segments.
Well stablished platform in
Nuclear Medicine
diagnosis in Spain and
Portugal.
Market leader in | #1 B2B tele-diagnostic | |
private oncology | company in Spanish | |
treatments in Spain. | with a leading position | |
in Spain, Chile and | ||
Colombia. | ||
With more than 6 million | ||
#3 player in preventive | diagnoses per year and | |
medicine by market | presence in 8 countries, | |
share in Spain. | ATRYS is an AI tools | |
integrator company. | ||
5
Health care sector with long term tailwins
Positioned in segments of the healthcare sector with long-term tailwinds
Ageing of the Spanish | Cancer Incidence2 | Healthcare | Healthcare | Healthcare |
expenditure (% GDP)3 | ||||
population1 | (Spain) | expenditure (% GDP)3 | expenditure (% GDP)3 |
01 | > 60 years | SPAIN | COLOMBIA | USA | ||||||
26% | 39% | Incidence | 9.0% | 9.9% | 6.2% | 7.5% | 16% | 20% | ||
>55 | ||||||||||
79% | ||||||||||
years old | ||||||||||
2020 | 2040 | 2015 | 2030 | 2015 | 2030 | 2015 | 2030 |
Healthcare demand increasingly exceeds health systems capabilities
02
Shortage of medical specialists in Spain (forecast) | # medical specialists | Shortage of medical | Waiting list for | |||||||||||
> 60 years age | specialists (Chile | medical specialist | ||||||||||||
(2027e) 4 | (2035e) 4 | (Spain 2021)4 | 2021)4 | attention (Spain 2006- | ||||||||||
2021)5 | 89 days | |||||||||||||
54 days | ||||||||||||||
9,000 | 17,765 | 18.1% | 11,768 | |||||||||||
2006 | 2021 | |||||||||||||
(1) | PopulationPyramid.net | 6 | ||||||||||||
(2) | Globocan 2018/SEOM; Applied Radiation oncology. Elmore et al.; Clin Transla. Oncol, 2017, Rodriguez et al. |
- Global Health Vizhub Data, OCDE Health working paper nº110
- Estudio Oferta-Necesidad de Especialistas Médicos 2021-2035', elaborado por el equipo EcoSalud de la Universidad de Las Palmas de Gran Canaria | 2 Instituto de Métricas y Evaluación de Salud de la Universidad de Washington
- Sistema Nacional de Salud y epadata.es
1. Prevention
Prevention overview
Atrys provides (i) personalized prevention medicine services
to employees (analysis, medical check-ups, etc.) and overall health environment assessment of the workplace implementing solutions and trainings within (i) occupational safety (ii) industrial hygiene (iii) ergonomics and (iv) psychosociology.
Atrys client base is composed of Companies ranging from small SMEs to large corporation that need to comply with the
existing prevention regulation.
Business line resulting from the merge with Aspy (2021).
Clients
Business Model | |||
Employees | Company | ||
Service Fee | |||
(€) | |||
Health surveillance service / Technical | |||
prevention service | |||
Health surveillance service / Technical prevention | |||
service | |||
KPIs | |||
+210 | +808 | 9 years | |
Branches and | Prevention | Average contract | |
Partner centers | specialist | term | |
+46,000 | 3ª player | 92% | |
by market share | client renewal | ||
Clients | |||
Spain | ratio | ||
7 | |||
Services | End user | M&A |
2. Diagnostics
Diagnostics overview
Telemedicine business leveraging delocalized specialist's of its
Business Model
own platform providing radiology, cardiology and ophthalmology services.
- Laboratory testing pathological anatomy and genetics testing through a wide network of laboratory specialists.
- Nuclear medicine diagnostic through radioactive isotopes to identify damaged or pathogenic tissue.
Atrys provides services to B2B clients hospitals (public and private) and B2C independently treated clients.
Recently acquired Chilerad, SIMM and Genetyca.
Patient | Insurance | Hospital |
Company | ||
Annual | Test Fee (€) |
Fee (€)
Test Fee (€)
Results
Test +
Service
Fee (€)
Results
Telemedicine
Labs/
Nuclear M
Clients (Spain)
Hospitals (Telemedicine) | Insurance C. (Labs & Nuclear) |
KPIs
+6.1mn | +36k | +300k | ||
Online | Nuclear medicine | Pathology & | ||
Diagnostics | diagnostics | molecular diagnostics | ||
1st | 90% | |
B2B tele-diagnostic company | Market share in | |
in Spanish | Chile tele-diagnostic | |
8 | ||
Services | End user | M&A |
3. Oncology
Oncology overview
Business Model
Medical oncology leader in Spain, providing oncology services (chemo & immunotherapy) in hospitals units.
Advanced radiotherapy / brachytherapy oncology services specializing in single-dose radiotherapy treatments.
Atrys provides services to both Public Administrations (tending to externalization) and Private Groups.
Health
Insurance
PatientCompany
Annual Fee (€)
Radiotherapy | |
Capitative fee | Centres / |
(€) | Medical |
Radiotherapy | oncology |
Fee (€) |
In 2022 acquired Medical oncology specialist Bienzobas and Initia as well as developed partnerships Celaya and Polanco hospitals in Mexico.
Clients
Radiotherapy / Medical oncology
KPIs
+100 | +3 | +5 | ||
Countries with | Radiotherapy | |||
Oncologists | ||||
cancer centers | units | |||
+40 | +60% | +80,000 | |
Spain market share | Oncology | ||
Hospitals | |||
private onco-patients | procedures | ||
9 | |||
Services | End user | M&A |
Case studies | Synergies maximization
✓ Atrys has proven a |
successful relationship |
Revenue (€k)
Llebalust
IOA(1)
Start of genetics
Labs in Lugo
Start of Nuclear
Medicine
Start of M. Oncology
IOA(2)
Start of
radiotherapy
centers in
2024
7.614
with Sanitas along the |
years enhancing its |
service offer to act as a |
one-stop-shop. |
Start of radiotherapy | 4.845 | ||||||||||
centers | |||||||||||
Second anatomical | 3.658 | ||||||||||
pathology laboratory | 2.695 | ||||||||||
253 | x1.8 | 464 | x1.8 | 847 | x3.2 | x1.4 | x1.3 | x1.6 | |||
2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
Precision medicine
Telemedicine
Laboratory
Nuclear
medicine
Radiotherapy
Medical oncology
✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| | | | | ✓ | ✓ |
| | | ✓ | ✓ | ✓ | ✓ |
| | | | | ✓ | ✓ 10 |
- Instituto de Oncología Avanazado: Reference radiotherapy centre that results from the collaboration with Hospital Sanitas CIMA and Atrys (Barcelona);
- Expects to open a New IOA in Madrid with Sanitas